A multi-center Phase 2 clinical trial in newly diagnosed infants with X-linked severe combined immunodeficiency (XSCID) between two months to two years of age
Latest Information Update: 19 Aug 2022
At a glance
- Drugs MB 107 (Primary)
- Indications Immunodeficiency disorders; X-linked genetic disorders
- Focus Registrational; Therapeutic Use
- Sponsors Mustang Bio
Most Recent Events
- 11 Aug 2022 According to a Mustang Bio media release, In 2023, the company expect to enroll the first patient in a pivotal multicenter Phase 2 clinical trial under Mustang Bio's Investigational New Product Drug Application (IND) to evaluate MB-107, a lentiviral gene therapy for the treatment of infants under the age of two with XSCID.
- 17 May 2021 According to Fortress Biotec media release, top-line data from this trial is expected in the second half of 2022.
- 02 Feb 2021 According to a Mustang Bio media release, the company plans to submit to enroll first patient in this trial in the second quarter of 2021.